Personalized Medicine: Elusive Dream or Imminent Reality?

@article{Lesko2007PersonalizedME,
  title={Personalized Medicine: Elusive Dream or Imminent Reality?},
  author={L J Lesko},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2007},
  volume={81}
}
  • L. Lesko
  • Published 1 June 2007
  • Medicine, Biology
  • Clinical Pharmacology & Therapeutics
The market for molecular diagnostic tests is predicted to grow at extraordinary rates over the next 10 years, fueled by pharmacogenetics and the elusive dream of personalized medicine. The challenge is managing the expectations of the medical community and the public at large that have already been set by speculation, promises, and the repeated exposure to headlines about genetic discoveries. Personalized medicine is a paradigm that exists more in conceptual terms than in reality, with only a… 
Personalized Medicine: Understanding Probabilities and Managing Expectations
TLDR
The stylized model of personalized medicine is more akin to a marketing tool than a literal prediction of the future, and is concluded that the arsenal of more personalized tools can be assimilated into current models of health care.
Safe and effective medicines for all: is personalized medicine the answer?
  • I. Cascorbi
  • Medicine, Biology
    Expert review of clinical pharmacology
  • 2010
TLDR
The impact of pharmacogenetics and pharmacogenomics, especially with regard to personalized medicine, in major medical indications is outlined and reflects the obstacles and chances taken in current daily practice.
Experimental Therapeutics: A Paradigm for Personalized Medicine
TLDR
Experimental therapeutics is the center of patient care, extending across the continuum of drug discovery, development, regulatory oversight, and utilization (DDRU) in practice, deploying translational medicine to advance disease treatment and promote patient wellness.
Therapeutic Targeting: A Crucible for Individualized Medicine
TLDR
The breathtaking scope of molecular diversity encoded in genetic polymorphisms—along with newly discovered levels of genetic regulation, including epigenetic modifications and microRNA, and approximately 106 protein states imposed by post-translational modifications with potential functional consequences—underscores the complexity of the goal of individualization through diagnostic and therapeutic targeting.
The Roadmap to Personalized Medicine
TLDR
The shift from palliation to curation with the revolution in regenerative medicine and therapeutic repair offered by individualized medicine has the potential to transform the efficiency of disease resolution, shortening hospital stays and decreasing health care expenditures.
Challenges, Opportunities, and Evolving Landscapes in Pharmacogenomics and Personalized Medicine An Industry Perspective
TLDR
This chapter provides an industry perspective on the emergence of the field of PGx focusing on the more mature DNA technologies.
Clinical and Translational Sciences: At the Intersection of Molecular and Individualized Medicine
TLDR
The emerging field of clinical and translational science drives the leading edge advancing discovery from the laboratory bench to evidence‐based practice at the bedside, and beyond to populations, to transform the clinical enterprise and create predictive, personalized, and preemptive paradigms for customized patient‐specific therapeutic strategies.
The future (or lack of future) of personalized prescription in psychiatry.
Personalized Medicines: Reforming Diagnostics and Therapeutics
TLDR
This paper gives a comprehensive view of PMs, the application of genomic and molecular data for developing therapies with unprecedentedly higher efficiencies, better safety, lower ADR’s, and reduced costs of therapies.
...
...

References

SHOWING 1-10 OF 18 REFERENCES
The Prospects for “Personalized Medicine” in Drug Development and Drug Therapy
  • J. Woodcock
  • Medicine
    Clinical pharmacology and therapeutics
  • 2007
TLDR
This paper evaluates the trajectory and promise of the next steps in progression of medical science toward greater mechanistic understanding of health, disease, and treatment for the currently problematic states of both drug development and therapy.
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
TLDR
VKORC1 haplotypes can be used to stratify patients into low-, intermediate-, and high-dose warfarin groups and may explain differences in dose requirements among patients of different ancestries.
New-Onset Atrial Fibrillation: Sex Differences in Presentation, Treatment, and Outcome
TLDR
Anticoagulants are underused in older women with AF relative to older men with AF, despite comparable risk profiles, and women receiving warfarin have a significantly higher risk of major bleeding, suggesting the need for careful monitoring of anticoagULant intensity in women.
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man
TLDR
S Warfarin is a more potent anticoagulant than R warfarin in man and the plasma T½ of R but not of S was significantly longer after multiple dosing than after a single dose.
New-onset atrial fibrillation
TLDR
It is concluded that hospitalization is not necessary for all patients with new-onset atrial fibrillation, and those in whom reversion to normal sinus rhythm occurs rapidly during digoxin therapy can be discharged.
Learning versus confirming in clinical drug development
  • L. Sheiner
  • Psychology, Biology
    Clinical pharmacology and therapeutics
  • 1997
Learning vs. confirming in clinical drug development
  • Clin. Pharmacol. Ther
  • 1997
...
...